Identification of STAT3 as a substrate of receptor protein tyrosine phosphatase T
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Protein tyrosine phosphatase (PTP) receptor T ( PTPRT ) is the most frequently mutated PTP in human cancers. However, the cell signaling pathways regulated by PTPRT have not yet been elucidated. Here, we report identification of signal transducer and activator of transcription 3 (STAT3) as a substrate of PTPRT. Phosphorylation of a tyrosine at amino acid Y705 is essential for the function of STAT3, and PTPRT specifically dephosphorylated STAT3 at this position. Accordingly, overexpression of normal PTPRT in colorectal cancer cells reduced the expression of STAT3 target genes. These studies illuminate a mechanism regulating the STAT3 pathway and suggest that this signaling pathway plays an important role in colorectal tumorigenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
Notch signalling: a simple pathway becomes complex
Bray, S. J. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2009 · Cited by 2,620
The STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278
Bowman, T., Garcia, R., Turkson, J., & Jove, R. (2000) · Oncogene · doi:10.1038/sj.onc.1203527 · Cited by 1,743
Corvinus, F. M., Orth, C., Moriggl, R., Tsareva, S. A., Wagner, S., Pfitzner, E. B., Baus, D., Kaufman, R., Huber, L. A., Zatloukal, K., et al. (2005) · Neoplasia · doi:10.1593/neo.04571 · Cited by 427
STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-α3
Liu, L., McBride, K. M., & Reich, N. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501643102 · Cited by 348
Validating Stat3 in cancer therapy
Darnell, J. E. (2005) · Nature Medicine · doi:10.1038/nm0605-595 · Cited by 307
Yamamoto, T., Sekine, Y., Kashima, K., Kubota, A., Sato, N., Aoki, N., & Matsuda, T. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02291-x · Cited by 250
Cited by
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Johnson, D. E., O'Keefe, R. A., & Grandis, J. R. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.8 · Cited by 3,110
Bollrath, J., Phesse, T. J., von Burstin, V. A., Putoczki, T., Bennecke, M., Bateman, T., Nebelsiek, T., Lundgren-May, T., Canli, Ö., Schwitalla, S., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.002 · Cited by 946
“Likewise, epigenetic impairment mutations in genes encoding negative regulators of STAT3 signaling, including the tyrosine phosphatase PTPRT and suppressor of cytokine signaling 3 (SOCS3), result in persistent STAT3 activation and associated tumorigenesis (He et al., 2003; Zhang et al., 2007).”
BackgroundThe molecular details of cytokine signaling via the JAK/STAT pathway
Morris, R., Kershaw, N. J., & Babon, J. J. (2018) · Protein Science · doi:10.1002/pro.3519 · Cited by 943
Aggarwal, B. B., Kunnumakkara, A. B., Harikumar, K. B., Gupta, S. R., Tharakan, S. T., Koca, C., Dey, S., & Sung, B. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04911.x · Cited by 649
Inside the human cancer tyrosine phosphatome
Julien, S. G., Dubé, N., Hardy, S., & Tremblay, M. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2980 · Cited by 495
Quantitative evidence for early metastatic seeding in colorectal cancer
Hu, Z., Ding, J., Ma, Z., Sun, R., Seoane, J. A., Scott Shaffer, J., Suarez, C. J., Berghoff, A. S., Cremolini, C., Falcone, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0423-x · Cited by 490
Ernst, M., Najdovska, M., Grail, D., Lundgren-May, T., Buchert, M., Tye, H., Matthews, V. B., Armes, J., Bhathal, P. S., Hughes, N. R., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34944 · Cited by 350
Strategies and Approaches of Targeting STAT3 for Cancer Treatment
Furtek, S. L., Backos, D. S., Matheson, C. J., & Reigan, P. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b00945 · Cited by 347
Protein tyrosine phosphatases in the JAK/STAT pathway
Xu, D. (2008) · Frontiers in Bioscience · doi:10.2741/3051 · Cited by 307
Veeriah, S., Brennan, C., Meng, S., Singh, B., Fagin, J. A., Solit, D. B., Paty, P. B., Rohle, D., Vivanco, I., Chmielecki, J., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900571106 · Cited by 299
Survival pathways in hypertrophy and heart failure: The gp130-STAT3 axis
Fischer, P., & Hilfiker-Kleiner, D. (2007) · Basic Research in Cardiology · doi:10.1007/s00395-007-0674-z · Cited by 272
The STAT3 pathway as a therapeutic target in head and neck cancer: barriers and innovations
Geiger, J. L., Grandis, J. R., & Bauman, J. E. (2016) · Oral Oncology · doi:10.1016/j.oraloncology.2015.11.022 · Cited by 193
Interleukin‐6 promotes tumorigenesis by altering DNA methylation in oral cancer cells
Gasche, J. A., Hoffmann, J., Boland, C. R., & Goel, A. (2011) · International Journal of Cancer · doi:10.1002/ijc.25764 · Cited by 178
“HCT116 colon cancer cells, which express IL-6R, served as positive controls.(31,36) As shown in Figure 1, a significant increase in pSTAT3 expression was visible in a subset of cell lines including HCT116, HaCaT, SCC056, SCC114 and SCC116 following IL-6 stimulation.”
BackgroundJulià, A., Ballina, J., Cañete, J. D., Balsa, A., Tornero‐Molina, J., Naranjo, A., Alperi‐López, M., Erra, A., Pascual‐Salcedo, D., Barceló, P., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23623 · Cited by 104
Meeusen, B., & Janssens, V. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2017.10.002 · Cited by 96
“Similar to PTPRD, PTPRT dephosphorylates STAT3 at Tyr705 (219), whereas it additionally targets paxillin through Tyr88 dephosphorylation (303).”
BackgroundInfluentialWakahara, R., Kunimoto, H., Tanino, K., Kojima, H., Inoue, A., Shintaku, H., & Nakajima, K. (2012) · Genes to Cells · doi:10.1111/j.1365-2443.2011.01575.x · Cited by 95
Kim, D. J., Tremblay, M. L., & DiGiovanni, J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010290 · Cited by 83
“PTPRT reportedly dephosphorylates Stat3 in colorectal cell lines, even though it is a receptor type PTP [28].”
BackgroundCritical analysis of the potential for targeting STAT3 in human malignancy
Grandis, J., & Peyser (2013) · OncoTargets and Therapy · doi:10.2147/ott.s47903 · Cited by 24
“17–20 Additionally, removal of the acetyl group from K685 of STAT3 by deacetylases, including SirT1, can lead to STAT3 downregulation.”
Characterization of prevalent genetic variants in the Estonian Biobank body-mass index GWAS
Abner, E., Batool, K., Taba, N., Nikopensius, T., Läll, K., Alekseienko, A., Eriksson, A., Rämö, J., Haapaniemi, H., Kariis, H. M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-64006-9 · Cited by 2
Metadata
- Authors
- Zhang, X., Guo, A., Yu, J., Possemato, A., Chen, Y., Zheng, W., Polakiewicz, R. D., Kinzler, K. W., Vogelstein, B., Velculescu, V. E., & Wang, Z. J.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2007-03-06
- Volume
- 104
- Issue
- 10
- Pages
- 4060-4064
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2037011709
- Cited by
- 210
- References
- 8
- FWCI
- 4.31
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.